Lung cancer treatment depends on two main factors: the type of lung cancer you have and how far it has spread. Most people receive some combination of surgery, radiation, chemotherapy, immunotherapy, or targeted therapy. The specific mix varies widely, from surgery alone for a small, early-stage tumor to multi-drug regimens for cancer that has spread beyond the chest.
There are two major types of lung cancer, and they’re treated quite differently. Non-small cell lung cancer (NSCLC) accounts for roughly 80 to 85 percent of cases and tends to grow more slowly. Small cell lung cancer (SCLC) makes up the remaining 15 to 20 percent, grows faster, and is almost always treated with chemotherapy and radiation rather than surgery.
Surgery for Early-Stage Lung Cancer
Surgery offers the best chance of a cure when cancer is caught early and hasn’t spread to distant parts of the body. It’s the primary treatment for stage I and stage II NSCLC, and sometimes for stage IIIA disease when the tumor can be fully removed. The type of operation depends on the tumor’s size and location.
A lobectomy, removing one of the lung’s lobes, is the most common surgery for early-stage lung cancer. The right lung has three lobes and the left has two, so most people retain significant lung capacity afterward. For very small tumors caught early and confined to one area, a surgeon may perform a wedge resection (removing a small wedge-shaped piece of lung tissue) or a segmentectomy (removing a slightly larger defined segment along with its blood vessels and airways). These smaller operations preserve more lung function but are only appropriate when imaging and testing confirm the cancer hasn’t spread within the lung. When cancer involves the central area of a lung or multiple lobes on the same side, a pneumonectomy, removal of the entire lung, may be necessary.
In small cell lung cancer, surgery plays a much smaller role. It’s occasionally used for the rare case caught very early, but most SCLC has already spread by the time it’s diagnosed, making surgery impractical.
Chemotherapy and When It’s Used
Chemotherapy uses drugs that kill rapidly dividing cells throughout the body. In lung cancer, it serves different purposes depending on the stage. For early-stage NSCLC, chemotherapy given after surgery (called adjuvant chemotherapy) helps destroy any cancer cells that may have been left behind. It can also be given before surgery (neoadjuvant chemotherapy) to shrink the tumor and make it easier to remove. For advanced NSCLC, chemotherapy is often a core part of treatment, typically using platinum-based drug combinations delivered in cycles.
For small cell lung cancer, chemotherapy is the backbone of treatment at every stage. In limited-stage SCLC, where cancer is confined to one side of the chest, chemotherapy is combined with radiation to the chest. In extensive-stage SCLC, where cancer has spread more widely, combination chemotherapy is used alongside immunotherapy as the standard first-line approach.
Immunotherapy’s Growing Role
Immunotherapy works by helping your immune system recognize and attack cancer cells. Lung cancer cells often produce a protein that acts like a “don’t eat me” signal to immune cells. Checkpoint inhibitors block that signal, allowing the immune system to do its job. Several of these drugs are now used in lung cancer treatment, including pembrolizumab, nivolumab, atezolizumab, and durvalumab. Some are given alone, others paired with chemotherapy or even with each other.
The combination of immunotherapy and chemotherapy before surgery has shown striking results. In a major clinical trial (CheckMate-816), patients with operable stage IB to IIIA NSCLC who received immunotherapy plus chemotherapy before surgery had significantly better long-term survival compared to those who received chemotherapy alone. Among those who achieved complete clearance of their cancer by the time of surgery, 24 percent of the combination group, five-year survival was 95 percent.
In extensive-stage small cell lung cancer, immunotherapy combined with chemotherapy has become the standard first-line treatment. For unresectable stage III NSCLC, immunotherapy is given after chemoradiation to help keep the cancer from returning.
Targeted Therapy and Biomarker Testing
Not all lung cancers are driven by the same genetic changes. Targeted therapies are drugs designed to attack cancer cells carrying specific mutations, often while sparing normal cells. This makes them generally more tolerable than traditional chemotherapy. Before starting treatment for advanced NSCLC, your tumor will be tested for a panel of genetic alterations, sometimes called biomarker testing or molecular profiling.
The most common targets and what they mean for treatment:
- EGFR mutations: Found in roughly 10 to 15 percent of NSCLC cases in Western populations and higher rates in East Asian populations. Several oral drugs block this growth signal, with osimertinib being the most widely used.
- ALK rearrangements: Present in about 3 to 5 percent of NSCLC. Multiple drugs target this alteration, including lorlatinib, alectinib, and brigatinib.
- KRAS mutations: One of the most common genetic changes in lung cancer, now treatable with sotorasib and adagrasib for a specific variant called KRAS G12C.
- ROS1 rearrangements: Rare but highly responsive to drugs like entrectinib and crizotinib.
- BRAF V600E mutations: Treated with a combination of two drugs that block related growth pathways.
- RET fusions: Targeted by selpercatinib and pralsetinib.
- MET alterations: Addressed with capmatinib or tepotinib.
- HER2 mutations and NTRK fusions: Less common but have approved targeted options.
Targeted therapy is primarily used in advanced or metastatic NSCLC, but it’s increasingly being used after surgery as well. Patients with early-stage tumors that carry EGFR or ALK mutations may now receive targeted drugs as adjuvant therapy to reduce the risk of recurrence.
Radiation Therapy Techniques
Radiation uses high-energy beams to destroy cancer cells in a specific area. It plays different roles depending on the situation: as a primary treatment when surgery isn’t possible, alongside chemotherapy for locally advanced disease, or after surgery to catch any remaining cells.
For small, early-stage tumors in patients who can’t have or decline surgery, stereotactic body radiation therapy (SBRT) delivers very high, precisely focused doses over just a few sessions, typically three to five treatments. SBRT is used for peripheral tumors (those at least 2 cm from the major airways) that are 5 cm or smaller, generally stage I to IIA. Because the beams are so tightly focused, damage to surrounding healthy tissue is minimized.
For larger or more centrally located tumors, conventional radiation therapy is delivered in smaller daily doses over several weeks. In stage III NSCLC that can’t be surgically removed, radiation is combined with chemotherapy (chemoradiation), often followed by immunotherapy. For small cell lung cancer, radiation to the chest is a critical part of treatment for limited-stage disease. Patients with SCLC who respond well to initial treatment may also receive preventive radiation to the brain, since small cell cancer has a high tendency to spread there.
Treatment by Stage at a Glance
For stage I NSCLC, surgery alone is often sufficient, though larger tumors may benefit from follow-up chemotherapy, targeted therapy, or immunotherapy. Stage II typically involves surgery plus pre- or post-operative treatment. Stage III is more complex: if the tumor can be removed, surgery is combined with chemoimmunotherapy before and sometimes after the operation. If surgery isn’t feasible, chemoradiation followed by immunotherapy is the standard approach. A recent update to national guidelines added a targeted therapy option for patients with unresectable stage III NSCLC carrying specific EGFR mutations, based on trial data showing progression-free survival of over 39 months compared to less than 6 months with placebo. Stage IV NSCLC, where cancer has spread to distant organs, is treated with systemic therapies: immunotherapy, targeted therapy (if a treatable mutation is found), chemotherapy, or combinations of these.
Small cell lung cancer follows a simpler framework. Limited-stage disease gets chemoradiation, often with immunotherapy. Extensive-stage disease gets chemotherapy plus immunotherapy, with radiation used to treat symptoms or prevent brain spread.
Managing Side Effects During Treatment
Each treatment modality carries its own set of side effects. Chemotherapy commonly causes fatigue, nausea, hair loss, and lowered blood counts that increase infection risk. Some chemotherapy drugs cause peripheral neuropathy, a tingling, burning, or numbness in the hands and feet that can make fine motor tasks difficult. Using handrails, wearing rubber-soled shoes, and being cautious with sharp or hot objects can help prevent injuries while sensation is impaired.
Radiation to the chest can cause skin irritation in the treated area, including redness, dryness, and peeling. Avoiding lotions or skin products right before treatment sessions helps reduce reactions. Radiation near the throat can cause difficulty swallowing, dry mouth, and mouth sores. Sucking on ice chips before and after chemotherapy sessions may ease mouth-related symptoms.
Immunotherapy side effects differ from those of chemotherapy because they stem from an overactivated immune system. Skin rashes, fatigue, and inflammation in organs like the lungs, liver, or thyroid are possible. Targeted therapies tend to have milder side effects overall, though the specific profile varies by drug. Skin rashes, diarrhea, and liver changes are among the most common. Your treatment team will monitor bloodwork and symptoms throughout your course of therapy and adjust as needed.